Erbb2 Gene Amplification - Histology

Relevant Publications

Whole genome sequencing of HER2-positive metastatic extramammary Paget\'s disease: a case report.

Issue Release: 2024

ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.

Issue Release: 2024

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.

Issue Release: 2024

Primary cutaneous apocrine carcinoma with RARA::NPEPPS fusion.

Issue Release: 2024

A gene expression-based classifier for HER2-low breast cancer.

Issue Release: 2024

Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience.

Issue Release: 2024

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.

Issue Release: 2024

[Clinical and pathological characteristics of ovary mature cystic teratoma squamous cell carcinoma and primary ovarian squamous cell carcinoma].

Issue Release: 2024

Molecular and clinical portrait of HER2-low invasive lobular carcinomas.

Issue Release: 2024

The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling.

Issue Release: 2024

HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.

Issue Release: 2024

Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.

Issue Release: 2024

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.

Issue Release: 2024

ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity.

Issue Release: 2024

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.

Issue Release: 2024

Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.

Issue Release: 2024

Landscape of HER2-low breast cancer: Insights from a six-year study on prevalence and clinicopathological characteristics.

Issue Release: 2024

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.

Issue Release: 2024

Whether specific genetic feature predicted immunotherapy efficacy: A case report.

Issue Release: 2024

ERBB2 amplification and HER2 expression in salivary duct carcinoma: Evaluation of scoring guidelines and potential for expanded anti-HER2 therapy.

Issue Release: 2023

How Should Biohazard Spills be Managed?

What is Action Potential?

How Does Histology Relate to Physical Therapy?

What are the Benefits of Improved Mass Spectrometry in Histology?

How is Mirror Backup Implemented in Histology?

Are There Any Safety Concerns with Using Acids in Histology?

What is Langerin (CD207)?

What Role Does Vendor Reputation Play?

How Does Peer Review Contribute to Integrity?

What is OSHA?

Partnered Content Networks

Relevant Topics